Lupus Nephritis
AUTLAutolus TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for AUCATZYL/Obecabtagene Autoleucel (AUTO1) (CD19 CAR-T) in Lupus Nephritis. The expected timing is based on the latest available company guidance and may change.
05/14/26:- LUMINA is enrolling after FDA alignment; Phase 2 LN data remains expected in 2028. 08/11/26:- LUMINA continues enrolling in five countries; Phase 2 LN data expected in 2028.
Verification
Confirm timing and program details against the company announcement or filing.